Universität zu Köln

Fischer, Kirsten, Al-Sawaf, Othman and Hallek, Michael (2020). Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematol.-Am. Soc. Hematol. Educ. Program (1). S. 357 - 363. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1520-4383

Full text not available from this repository.

Abstract

Recent developments in the management of chronic lymphocytic leukemia (CLL) have moved the standard of care away from chemoimmunotherapy to targeted agents such as oral kinase inhibitors or BCL-2 antagonists, alone or in combination with anti-CD20 antibodies. Two different treatment approaches have evolved: continuous, indefinite treatment and, more recently, fixed-duration combination treatment. With venetoclax-based treatment, there is a requirement to follow the established guidelines for close monitoring during initiation and ramp up, to reduce the risk of tumor lysis syndrome. The patient's risk should be assessed before the initiation of venetoclax. Appropriate management strategies should be used, including uricosuric agents, hydration, and routine laboratory monitoring, per guidelines. With early identification, immediate management, and dose adjustments, we suggest that tumor lysis syndrome and other toxicities, such as neutropenia and infections, with venetoclax-based treatment can be dealt with successfully.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Fischer, Kirsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Al-Sawaf, Othman UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-308701
DOI:	10.1182/hematology.2020000120
Journal or Publication Title:	Hematol.-Am. Soc. Hematol. Educ. Program
Number:	1
Page Range:	S. 357 - 363
Date:	2020
Publisher:	AMER SOC HEMATOLOGY
Place of Publication:	WASHINGTON
ISSN:	1520-4383
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language OPEN-LABEL; OBINUTUZUMAB; RISK; CHLORAMBUCIL; CLL; PROPHYLAXIS; MULTICENTER; RITUXIMAB; IBRUTINIB; CHILDREN Multiple languages Education, Scientific Disciplines; Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/30870